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In rhesus monkey antinociception experiments, the cinnamoylaminomorphinone opioid 
antagonist cloeinnamox at a dose of 0.1 mg/kg irreversibly inactivated 88% of the mu opioid receptor 
population (as calculated by in vivo Furchgott analysis) whereas kappa receptors remained unaffected 
(1). In contrast, in vitro radioligand binding assays showed only a moderate mu : delta : kappa - 
selectivity of clocinnamox (30 : 1.5 : 1; ref. 2). This apparent discrepancy was investigated in mice 
using both in vitro and ex vivo opioid binding studies. 
Opioid receptor binding was determined using [3H]DAMGO for mu-, [3H]-p-C1-DPDPE for 
delta-, and [3H]bremazoeine in presence of 1 I.tM DAMGO and 1 ~tM DPDPE for kappa opioid 
receptors in whole mouse brain membranes (buffer: 50 mM Tris-HC1 pH 7.4, 0.1 mM 
phenylmethylsulfonyl fluoride, 1% dimethyl sulfoxide; 2 h incubation at 25oc). Clocinnamox showed 
pseudo-Ki and Ki values of 0.25 nM for mu receptors (pKi, 8.41 _+ 0.07; Hill slope, 1.0 -+ 0.1; means 
_+ S.E.), 1.6 nM for delta receptors (pKi, 8.09 -+ 0.17; Hill slope, 0.9 -+ 0.2), and 7.2 nM for kappa 
receptors (pKi, 7.80 + 0.9; Hill slope, 0.1 _+ 0.1), corresponding to a 29 : 5 : 1-selectivity for mu : 
delta : kappa, thus confirming previous studies. Similarly, clocinnamox' agonistic codeinone 
derivative, methoclocinnamox (3), yielded pseudo-Ki and Ki values of 0.46 nM for mu receptors 
(pKi, 9.34 _+ 0.16; Hill slope, 1.1 + 0.1), 4.5 nM for delta receptors (pKi, 8.35 _+ 0.21; Hill slope, 
1.2 _+ 0.1), and 29 nM for kappa receptors (pKi, 7.54 _+ 0.12; Hill slope, 1.1 _+ 0.3), corresponding 
to a 63 : 6 : 1-selectivity for mu : delta : kappa. Thus, the present data are in accordance with 
previously published reports from other laboratories. 
In a washout experiment, naltrexone (1 I.tM), clocinnamox and methoclocinnamox (10 nM and 
1 ktM each) were added to whole mouse brain membranes, incubated for 2 hours (i.e., binding 
competition experiment condition), then repeatedly washed with 150 volumes/wet weight fresh 
medium (3) and further incubated for up to 8 h at 25oc to allow for ligand dissociation. Aliquots of 
these membranes were tested for mu-, delta-, and kappa-opioid receptor binding at the end of the 
competition binding incubation period, and after 2 h (2 washes) and 8 h (4 washes). Neither the 
binding inhibition mediated by 10 nM clocinnamox nor that of 1 ~tM clocinnamox could be reversed 
from mu receptors even after 8h washing (e.g., 1 ~tM, 99.8% - >  94%), whereas it was at least 
partially reversible at delta (99.7% -> 69%) and kappa (86% -> 62%) receptors. The binding inhibition 
mediated by methoclocinnamox, however, was at least partially reversible at all three opioid receptor 
subtypes. Naltrexone-mediated binding inhibition was completely reversed at the first washout period 
tested, i.e. 2 h (2 washes). In summary, the in vitro binding data indicate that although clocinnamox 
interacts with all three opioid receptor subtypes, only its interaction with the mu receptor is of an 
irreversible nature. 
Similar results were obtained in ex vivo binding experiments. Mice were treated with 1 - 10 
mg/kg clocinnamox i.p., sacrificed 1 h to 28 d later, their brains homogenized and opioid receptor 
binding measured. Only ex vivo binding to mu receptors was inhibited by clocinnamox, delta and 
kappa receptor binding remained unaffected even after a clocinnamox pretreatment time of only 1 h. 
The [3H]DAMGO binding inhibition after clocinnamox was due to a decrease in receptor density 
whereas the affinity of the radioligand for the mu receptors remained essentially unchanged as already 
demonstrated in a previous study (5). After the acute and dose-dependent decrease of the mu receptor 
population by clocinnamox (1 h pretreatment; 1 mg/kg, 44 _+ 3 % inhibition; 3.2 mg/kg, 90 +- 1%; 10 
mg/kg, 90 + 2 %)., ex vivo [3H]DAMGO binding reappeared with a half-lifes of 4.2 d ( after 1 mg/kg 
clocinnamox), 2.7 d (3.2 mg/kg), and 2.8 d (10 mg/kg). 
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The reappearance of mu opioid receptors was partially blocked by the protein synthesis 
inhibitor cycloheximide. Following previously published experimental protocols (6, 7), a loading dose 
of 50 mg/kg cycloheximide and a subsequent administration of 5 mg/(kg.h) cycloheximide by 
implanted osmostic minipumps was used to inhibit protein synthesis. Cycloheximide alone did not 
significantly change ex vivo [3H]DAMGO binding over 48 h (inhibition < 7%), after which the 
experiment had to be terminated because of the considerable side effects of cycloheximide. 
Administration of 3.2 mg/kg clocinnamox alone acutely decreased [3H]DAMGO binding to 12 + 2 % 
of control.  Binding partially recovered within the 48 h time period, exactly as expected from the 
previous time course experiments. In contrast, ex vivo [3H]DAMGO binding to brain membranes of 
sham-operated mice (implantation of empty minipumps) did not change over the whole time course. 
Finally, when mice were given both clocinnamox and cycloheximide, mu receptors acutely were 
decreased to about the same amount (i.e., 9 + 2 % of the control population) as in the mice treated with 
clocinnamox alone. The reappearance of [3H]DAMGO binding, however, was decreased in 
comparison to the mice treated with clocinnamox alone: After 24 h, [3H]DAMGO binding after 
clocinnamox alone had returned to 49 + 6 % of control, whereas it was 26 + 1 %  after combined 
administration of clocinnamox and cycloheximide. The respective values after 48 h were 62 + 4 % for 
clocinnamox alone and 34 + 5 % for the clocinnamox-cycloheximide combination. Ex vivo delta- and 
kappa opioid receptor binding remained unaffected by either clocinnamox or cycloheximide alone or 
their combination. 
We also compared the time course of ex vivo [3H]DAMGO binding recovery after 3.2 mg/kg 
clocinnamox with estimates of q, the fraction of available receptors, as determined by Furchgott 
analysis of data obtained in warm-water tail withdrawal experiments. To that end, published time 
course experiments (Fig. 5 of ref.8) using morphine as an antagonist were repeated by different 
experimenters in our laboratory and extended to a time span of 16 days. Data were pooled and 
analyzed as detailed previously (1) to obtain q, the fraction of available receptors according to 
Furchgott (9) and Black and Left (10). 3.2 mg/kg clocinnamox acutely depressed the q value to 0.3 (1 
being the value for the control population). Q values returned with a half-life of 2.0 d, which was close 
to that of 2.7 d obtained when analyzing recovery of ex vivo [3H]DAMGO binding. Thus, Furchgott 
analysis of behavioral data again seemed to provide estimates of receptor population changes of 
reasonably high confidence. 
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